Genetically modified human natural killer cell lines

摘要

The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

主权项

1. A method for assaying a candidate antibody for efficacy in killing a cancerous or infected cell, which method comprises:
(i) selecting a candidate antibody that specifically binds to an antigen that is expressed by a tumor or infected cell, and that also binds to an NK-92 cell modified to express an FyγRIII-A receptor on a surface of the NK-92 cell, wherein said NK-92 cell is available from American Type Culture Collection (ATCC) as Accession No. PTA-6670, (ii) incubating in vitro a cancerous or infected cell with the candidate antibody to form a mixture under a condition that the antibody can bind to the cancerous or infected cell; (iii) incubating in vitro the mixture with the modified NK-92 cell under conditions wherein the modified NK-92 cell is capable of killing said cancerous or infected cell; and (iv) determining the efficacy of said antibody in killing said cancerous or infected cell.